Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serelaxin To Lower Portal Pressure in Patients with Cirrhosis and Portal Hypertension (STOPP)
2015-004031-12Phase 2Terminated
- Sponsor
- University of Edinburgh
- Start
- May 2018
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of serelaxin in Portal Hypertension (PH) and Cirrhosis, sponsored by University of Edinburgh. Primary endpoint: Change from baseline in fasting hepatic venous pressure gradient (HVPG) after 2 hours serelaxin infusion. Started May 2018; status: terminated.
02
Drugs
serelaxin
03
Conditions
Portal Hypertension (PH)Cirrhosis
Beyond the preview
Go deeper on 2015-004031-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004031-12.